Investigator-Initiated Clinical Trial AgreementInvestigator-Initiated • March 22nd, 2022
This Investigator-Initiated Clinical Trial Agreement (“Agreement”) is made as of this {DAY} day of {MONTH}, {YEAR} (the “Effective Date”) by and between the Board of Regents of the University of Wisconsin System on behalf of the University of Wisconsin-Madison, a public higher educational institution with an address at 21 N. Park Street Suite 6301, Madison, WI 53715 (“Institution”) and {COMPANY NAME}, a corporation having its principal place of business at {COMPANY ADDRESS} (“Company”). Company and Institution are herein referred to collectively as “Parties.” Individually, each of Institution and Company is a “Party.”
Investigator-Initiated Clinical Trial AgreementInvestigator-Initiated • July 3rd, 2019 • Annovis Bio, Inc. • Pharmaceutical preparations • California
This Clinical Trial Agreement (“Agreement”) is made and entered into effective as of the full execution hereof (“Effective Date”), by and between The Regents of the University of California, a California constitutional corporation, on behalf of its San Diego campus, located at 9500 Gilman Drive, La Jolla, CA 92093, California (“Institution”), and QR Pharma, Inc., a Delaware corporation having its principal place of business at 1055 Westlakes Drive, Suite 300, Berwyn PA 19312 (“Company”), (each may be individually referred to as a “Party” and collectively, as “the Parties”).
Investigator Initiated Clinical Trial AgreementInvestigator Initiated • June 22nd, 2017
THIS AGREEMENT is entered into effective as of (the “Effective Date”) by and between Regents of the University of Minnesota (the "University"), a public educational institution and a Minnesota constitutional corporation, and (the “Sponsor”), a . This Agreement is entered into by the University through its Office of Sponsored Projects Administration.
